Condition: Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer · Sponsor: BioEclipse Therapeutics
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with monotherapy dose escalation followed by combination cohorts.
This description comes directly from the study's public registry record.
Jennifer Lindal · 206-229-5827 · clinical@bioeclipse.com
Pamela Contag, PhD Chief Executive Officer · info@bioeclipse.com
Always discuss trial participation with your own doctor first.
| HonorHealth Research Institute | Scottsdale, Arizona, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04282044